Fondaparinux: a new synthetic and selective inhibitor of Factor Xa

被引：22

作者：

Bauer, KA ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Boston, MA 02215 USA

[2] VA Boston Healthcare Syst, Hematol Sect, Boston, MA USA

[3] Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA

来源：

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2004年 / 17卷 / 01期

关键词：

fondaparinux; heparin; pentasaccharide; pharmacokinetics; thromboprophylaxis; venous thromboembolism; surgery; acute coronary syndromes;

D O I：

10.1016/j.beha.2004.03.004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Fordaparinux (Arixtra(R)) is the first synthetic selective Factor Xa inhibitor. Its efficacy and safety in the prevention of venous thromboembolism (VTE) was first studied in patients undergoing major orthopedic surgery, a setting in the highest risk category for postoperative thrombotic complications. Low-molecular-weight heparins are frequently used in this setting, but the rates of VTE still range between 15% and 33%. In large clinical trials, fordaparinux started 6 hours postoperatively was significantly more effective than enoxaparin in preventing WE in patients undergoing total hip replacement, total knee replacement or hip fracture surgery. The benefit of extended fondaparinux prophylaxis after hip fracture surgery was also investigated. Other trials have demonstrated that fondaparinux is efficacious in the prevention of WE in other patient populations at risk of thrombosis and in the treatment of symptomatic VTE.

引用

页码：89 / 104

页数：16

共 51 条

[31]

Lormeau JC, 1995, THROMB HAEMOSTASIS, V74, P1474

[32]

LORMEAU JC, 1993, THROMB HAEMOSTASIS, V69, P152

[33] Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers [J].